A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors

Study ATX-898-101 is a phase 1/2 open-label study evaluating the safety, tolerability, pharmacokinetic, and preliminary efficacy of ATX-898 as monotherapy and in combination with anti-neoplastic agents in selected solid tumors. This study consists of 2 parts. Part 1 evaluates ATX-898 as monotherapy and Part 2 evaluates ATX-898 in combination with anti-neoplastic agents of interest. Both parts will consists of a dose escalation portion and a dose expansion portion.

Trial Details

NCT ID
NCT07767474
Phase
PHASE1 / PHASE2
Sponsor
Antares Therapeutics, Inc
Status
RECRUITING
Cancer Type
HER2 Negative Breast Cancer
Interventions
  • ATX-898
  • ATX-898, fulvestrant, ribociclib
Locations (sample)
  • Fort Worth, Texas, United States|32.72541,-97.32085
  • Houston, Texas, United States|29.76328,-95.36327
  • San Antonio, Texas, United States|29.42412,-98.49363
  • West Valley City, Utah, United States|40.69161,-112.00105
  • Fairfax, Virginia, United States|38.84622,-77.30637

Key Eligibility Criteria

  • Has histologically or cytologically confirmed advanced solid tumor malignancy that is metastatic or locally advanced and unresectable
  • Is ≥18 years of age at the time of signing the informed consent form
  • ECOG performance status score of 0 or 1
  • Adequate organ function

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Negative Breast Cancer Trials on Trialify →